Skip to content

Author's details

Reviewer's details

Pleural Effusion

Key Messages

  • Pleural effusion is caused by an imbalance between fluid production and absorption in the pleural space.
  • In Nigeria, tuberculosis is the leading cause, responsible for most exudative effusions.
  • Symptoms commonly include dyspnea, pleuritic chest pain, and dry cough.
  • Diagnostic thoracentesis with Light’s criteria and ADA testing is essential for accurate classification.
  • Treatment focuses on thoracentesis for relief and addressing the underlying cause such as TB, infection, or malignancy.
Background

Accumulation of fluid in pleural space due to imbalance between production and absorption. Classified as transudative (increased hydrostatic pressure/decreased oncotic pressure) or exudative (pleural inflammation/infection/malignancy).

Local Epidemiology: In Nigeria, infectious causes dominate (80%), with tuberculosis responsible for 60-70% of exudative effusions. Parapneumonic effusions and malignancy are next common. (Obaseki et al., 2014; Nigerian Medical Journal)

Discussion

Symptoms & Clinical Features

  • Dyspnea (most common), pleuritic chest pain, dry cough
  • Physical signs: Dullness to percussion, reduced breath sounds, decreased vocal fremitus
  • Traditionally: Egophony (e to a change) above effusion level

Differential Diagnosis

Based on Light's criteria differentiation:

  • Transudative: Heart failure, cirrhosis, nephrotic syndrome, hypoalbuminemia
  • Exudative: TB, parapneumonic, malignancy (lung, breast, lymphoma), pulmonary embolism

Investigations

  1. Diagnostic thoracentesis: Essential for classification
  2. Light's criteria: Exudate if pleural/serum protein >0.5, LDH >0.6, or pleural LDH >2/3 ULN
  3. Adenosine deaminase (ADA): >40 U/L suggests TB (sensitivity 92%, specificity 90% in high-TB settings)
  4. Cytology: For malignant effusions
  5. Imaging: Chest X-ray (blunted costophrenic angle), ultrasound (loculations, guidance), CT (underlying pathology)
    Nigerian studies: ADA remains cost-effective first-line test; Xpert MTB/RIF on pleural fluid increases TB yield by 30% (Nwachukwu et al., 2018)

Treatment

  • Therapeutic thoracentesis: For symptomatic relief (limit 1.5L per session)
  • Treat underlying cause:
    • TB: Standard Anti-tuberculous therapy; steroids controversial
    • Parapneumonic: Antibiotics; tube drainage if pH<7.2 or loculated
    • Malignant: Repeated drainage, pleurodesis (talc/doxycycline), indwelling catheter
  • Empyema: Surgical drainage/decortication with or without DNAse/Alteplase as fibrinolytic

Follow-up

  • 2-4 weeks post-treatment initiation
  • Monitor for re-accumulation, response to therapy
  • Repeat imaging until resolution

Prevention & Control

  • Early treatment of pneumonia and TB prevents complication to effusion/empyema
  • Proper chest tube management to prevent empyema

Conclusion and Experience from the clinic

In Nigeria, a systematic approach with ADA and thoracentesis is crucial for diagnosing TB pleural effusion, the most common cause. Ultrasound availability improves procedural safety and diagnostic accuracy.

Simple uncomplicated pleural effusion may be easily handled; some patients present with all sorts of improvised chest tubes including urethral catheter. These are placed at some PHCs or General Hospitals. Complicated pleural effusion including multiloculated empyema thoracic are nightmare to pulmonologist, eventually a cardiothoracic consult may be required where thoracotomy and decortication of the pockets of pus are paramount. Hence, early presentation and appropriate procedures and use of standard consumables could shorten hospital stay and morbidities and mortalities associations with unsolicited improvisions. 

Interesting patient case

A 35-year-old man presents with progressive shortness of breath, pleuritic chest pain, and a dry cough. Examination reveals dullness to percussion and reduced breath sounds on the right lower lung field. Chest X-ray confirms a moderate pleural effusion, and diagnostic thoracentesis shows exudative fluid with high ADA levels, suggesting tuberculosis. He undergoes therapeutic thoracentesis for symptom relief and is started on anti-tuberculous therapy. Follow-up at 2–4 weeks is planned to monitor resolution.

Further readings
  • Obaseki DO, et al. (2014). Aetiology of pleural effusion in a Nigerian tertiary hospital. Nigerian Medical Journal.
  • Light RW. (2002). Pleural Diseases. Clinical Chest Medicine.
  • Golden et al. Keep the old, in with the new: The changing face of pleural effusions. African Journal of Thoracic and Critical Care Medicine. 2021;27(4):182.
  • Nwafor IA, Nnakenyi EF, Eze JC, Nwidenyi IO. Management of malignant pleural effusion (MPE) in a tertiary hospital in a low-income country: challenges and prospects. Ibom Medical Journal. 2020;13(3):1–14.
  • Agossou M, Bashi BJ, Azon-Kouanou A, Zannou DM, Ade G, Houngbe F. Pleural effusions at the Internal Medicine Unit, Centre National Hospitalier Universitaire, Cotonou, Benin. African Journal of Respiratory Medicine. 2013;9(1):1–7.

More topics to explore

Author's details

Reviewer's details

Pleural Effusion

Accumulation of fluid in pleural space due to imbalance between production and absorption. Classified as transudative (increased hydrostatic pressure/decreased oncotic pressure) or exudative (pleural inflammation/infection/malignancy).

Local Epidemiology: In Nigeria, infectious causes dominate (80%), with tuberculosis responsible for 60-70% of exudative effusions. Parapneumonic effusions and malignancy are next common. (Obaseki et al., 2014; Nigerian Medical Journal)

  • Obaseki DO, et al. (2014). Aetiology of pleural effusion in a Nigerian tertiary hospital. Nigerian Medical Journal.
  • Light RW. (2002). Pleural Diseases. Clinical Chest Medicine.
  • Golden et al. Keep the old, in with the new: The changing face of pleural effusions. African Journal of Thoracic and Critical Care Medicine. 2021;27(4):182.
  • Nwafor IA, Nnakenyi EF, Eze JC, Nwidenyi IO. Management of malignant pleural effusion (MPE) in a tertiary hospital in a low-income country: challenges and prospects. Ibom Medical Journal. 2020;13(3):1–14.
  • Agossou M, Bashi BJ, Azon-Kouanou A, Zannou DM, Ade G, Houngbe F. Pleural effusions at the Internal Medicine Unit, Centre National Hospitalier Universitaire, Cotonou, Benin. African Journal of Respiratory Medicine. 2013;9(1):1–7.

Content

Author's details

Reviewer's details

Pleural Effusion

Accumulation of fluid in pleural space due to imbalance between production and absorption. Classified as transudative (increased hydrostatic pressure/decreased oncotic pressure) or exudative (pleural inflammation/infection/malignancy).

Local Epidemiology: In Nigeria, infectious causes dominate (80%), with tuberculosis responsible for 60-70% of exudative effusions. Parapneumonic effusions and malignancy are next common. (Obaseki et al., 2014; Nigerian Medical Journal)

  • Obaseki DO, et al. (2014). Aetiology of pleural effusion in a Nigerian tertiary hospital. Nigerian Medical Journal.
  • Light RW. (2002). Pleural Diseases. Clinical Chest Medicine.
  • Golden et al. Keep the old, in with the new: The changing face of pleural effusions. African Journal of Thoracic and Critical Care Medicine. 2021;27(4):182.
  • Nwafor IA, Nnakenyi EF, Eze JC, Nwidenyi IO. Management of malignant pleural effusion (MPE) in a tertiary hospital in a low-income country: challenges and prospects. Ibom Medical Journal. 2020;13(3):1–14.
  • Agossou M, Bashi BJ, Azon-Kouanou A, Zannou DM, Ade G, Houngbe F. Pleural effusions at the Internal Medicine Unit, Centre National Hospitalier Universitaire, Cotonou, Benin. African Journal of Respiratory Medicine. 2013;9(1):1–7.
Advertisement

Are you a Medical Doctor?